z-logo
Premium
Current natural therapies in the treatment against glioblastoma
Author(s) -
Erices José Ignacio,
Torres Ángelo,
Niechi Ignacio,
Bernales Isabel,
Quezada Claudia
Publication year - 2018
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6170
Subject(s) - angiogenesis , radiation therapy , glioblastoma , medicine , curcumin , cancer research , apoptosis , in vivo , chemotherapy , pharmacology , biology , bioinformatics , microbiology and biotechnology , biochemistry
Glioblastoma (GBM) is the most common and aggressive brain tumor, which causes the highest number of deaths worldwide. It is a highly vascularized tumor, infiltrative, and its tumorigenic capacity is exacerbated. All these hallmarks are therapeutic targets in GBM treatment, including surgical removal followed by radiotherapy and chemotherapy. Current therapies have not been sufficient for the effective patient's management, so the classic therapies have had to expand and incorporate new alternative treatments, including natural compounds. This review summarizes natural products and their physiological effects in in vitro and in vivo models of GBM, specifically by modulating signaling pathways involved in angiogenesis, cell migration/invasion, cell viability, apoptosis, and chemoresistance. The most important aspects of natural products and their derivatives were described in relation to its antitumoral effects. As a final result, it can be obtained that within the compounds with more evidence that supports or suggests its clinical use are the cannabinoids, terpenes, and curcumin, because many have been shown to have a significant effect in decreasing the progress of GBM through known mechanisms, such as chemo‐sensitization or decrease migration and cell invasion. Natural compounds emerge as promising therapies to attack the progress of GBM.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here